New drugs for hepatitis C virus (HCV)
- 30 April 2000
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 14 (2) , 293-305
- https://doi.org/10.1053/bega.1999.0077
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studiesJournal of Molecular Biology, 1999
- Are all Type I human interferons equivalent?Journal of Viral Hepatitis, 1998
- A multicenter, randomized trial of daily, high dose interferon-alpha 2b for the treatment of chronic hepatitis C: Prospective stratification by viral burden and genotypeGastroenterology, 1998
- Pilot study of intron-A and ribavirin vs intron-A and amantadine in interferon non-responders with chronic hepatitis CGastroenterology, 1998
- Epidemiology of hepatitis CHepatology, 1997
- A Steady-state and Pre-steady-state Kinetic Analysis of the NTPase Activity Associated with the Hepatitis C Virus NS3 Helicase DomainJournal of Biological Chemistry, 1996
- A Novel Sequence Found at the 3′-Terminus of Hepatitis C Virus GenomeBiochemical and Biophysical Research Communications, 1995
- An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis CJournal of Hepatology, 1993
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989